top of page

Introducing Virostem CAR-T and Stem Cell Production Pipeline

Affordable and accessible CAR-T cell cancer treatments

Virostem Biotechnology is a leading research and development company also active in the fields of stem cells and CAR-T cell therapy.


CAR-T is an approved cancer treatment in America, Europe and Japan, and its manufacturing process is a trade secret among international competitors. Thanks to its own research and development studies, Virostem is capable of designing, manufacturing and implementing this technology at-scale and completely in-house. CAR-T cell cancer treatments currently cost between $250,000-$600,000 per patient worldwide and is largely inaccessible to most patients. Virostem aims to leverage its unique manufacturing process and experience to enable personalized, and mass production of CAR-T products for patients and hospitals.

antibody antigen.jpg
bottom of page